Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 16/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4136008 | 0.92 | DAGLA (0.41) | MCHR1HRH3DAGLA | |
| SCHEMBL4133535 | 0.87 | HRH3 (0.43) | MCHR1KCNH2HRH3HDAC8HDAC6 | |
| SCHEMBL4134993 | 0.82 | FAAH (0.38) | MCHR1HDAC6 | |
| SCHEMBL4140997 | 0.82 | USP30 (0.39) | KCNH2HRH3 | |
| SCHEMBL4136050 | 0.81 | CASP3 (0.39) | KCNH2HRH3 | |
| SCHEMBL4143084 | 0.80 | KCNH2 (0.47) | MCHR1KCNH2HTR1AHRH3HTR2C | |
| SCHEMBL4136270 | 0.77 | BACE1 (0.38) | KCNH2HRH3 | |
| SCHEMBL4139555 | 0.77 | GPR84 (0.40) | KCNH2HRH3 | |
| SCHEMBL4149013 | 0.74 | DRD3 (0.44) | KCNH2HTR1AHRH3 | |
| SCHEMBL4143078 | 0.74 | PDE4A (0.41) | KCNH2HTR1AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | MCHARDY STANTON FURST | 2009-06-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163482-A1 | TETRALINES ANTAGONISTS OF THE H-3 RECEPTOR | HRH3, HRH4, HRH1 | MCHR1 287/4885KCNH2 657/4885HTR1A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.